PHM.MC Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:35):

Stats
Dzisiejszy wolumen	48 516.00
Średni wolumen	39 000.00
Kapitalizacja rynkowa	555.51M
EPS	€0 ( 2024-04-24 )
Następna data zysków	( €0 ) 2024-07-25
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	283.09
ATR14	€0.0730 (0.23%)

Wolumen Korelacja

Długi: -0.07 (neutral)

Krótki: -0.11 (neutral)

Signal:(42.856) Neutral

Pharma Mar, S.A. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharma Mar, S.A. Korelacja - Waluta/Towar

-0.18
( neutral )

0.52
( weak )

0.00
( neutral )

-0.21
( neutral )

-0.49
( neutral )

Pharma Mar, S.A. Finanse

Annual	2023
Przychody:	€158.15M
Zysk brutto:	€144.86M (91.60 %)
EPS:	€0.0635

FY	2023
Przychody:	€158.15M
Zysk brutto:	€144.86M (91.60 %)
EPS:	€0.0635

FY	2022
Przychody:	€196.34M
Zysk brutto:	€182.70M (93.05 %)
EPS:	€2.73

FY	2021
Przychody:	€229.83M
Zysk brutto:	€213.39M (92.85 %)
EPS:	€5.14

Financial Reports:

No articles found.

Pharma Mar, S.A.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.